Background: Investigating and evaluating possible alternative therapeutic strategies to control hepatocellular carcinoma (HCC) is a critical need because of its high prevalence and being one of the most lethal cancers. Curcumin and taurine showed potent anti-tumor activities in pre-clinical and clinical studies by targeting multiple pathways. Thus, this study was designed to assess the effect of a combined treatment consisted of curcumin, piperine, and taurine on circulating levels of interleukin-10 (IL-10), and microRNAs miR-141 and miR-21. Methods: Twenty eligible HCC patients administrated an oral dose of 4 g curcumin, 40 mg piperine, and 500 mg taurine daily for three successive treatment cycles, each was a 30-day. The level of IL-10 along with the expression levels of miR-141, and miR-21 were monitored in serum before starting the treatment and after each cycle. Patients were followed-up for a period of 24 months. Results: The combined treatment was able to produce a significant decrease in the levels of serum IL-10, and miR-21 while it resulted in a non-significant up-regulation of serum miR-141 expression level. At the end of the follow-up period, the median overall survival (OS) rate was found to be 17.00 months with a worse OS in patients with high baseline levels of circulating IL-10 and miR-21 compared to those with low levels. In contrast, a low baseline level of circulating miR-141 was associated with poor prognosis. Conclusions: The combined treatment may be able to increase the OS rate by altering the circulating level of IL-10 and miR-21.
Introduction
Hepatocellular carcinoma (HCC) is the commonest primary cancer of the liver representing the fifth and the eighth largest cause of cancer in men and women, respectively.
Further, it is considered the third most lethal cancer worldwide with about 700,000 deaths reported annually (1) .
Surgical resection offers a limited treatment option for only about 20% of HCC patients because of several factors,
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A combined treatment of curcumin, piperine, and taurine alters the circulating levels of IL-10 and miR-21 in hepatocellular carcinoma patients: a pilot study such as tumor size, multifocality and vascular invasion with a recurrence rate of post-surgery as high as 50% (2) . In the same context, liver transplantation is another option offered only to early-stage HCC patients. However, the lack of donor organs makes the number of eligible patients small. Moreover, the prompt and frequent reappearance of HCC in the transplanted organ results in severely limited effectiveness (3, 4) . Many alternative approaches have limited usefulness and are applicable to patients with localized liver tumors only (5) (6) (7) .
Using natural agents in cancer treatment is promising because of their minimal toxicity to humans compared to conventional chemotherapies and their ability to target numerous signaling pathways which is beneficial because malignant transformation and progression are multistage processes caused by gene alterations in more than one signaling pathway (8) .
Turmeric, the rhizome of Curcuma longa, is widely used as a spice, coloring agent, and as a medicine for a variety of ailments. Curcuminoids are polyphenolic compounds that represent the primary chemical constituents in turmeric with the most important and abundant curcuminoids is curcumin (diferuloylmethane) (9) . It has been reported that curcumin exhibits an anticancer activity against different cancer types including skin, lung, gastrointestinal, hepatic, and hematologic malignancies primarily via modulating the expression of oncogenes and tumor suppressor genes, inducing cell cycle arrest and apoptosis, and inhibiting angiogenesis and metastasis (10, 11) . In a prior phase I clinical trial, curcumin was found to be well tolerated at a dose as high as 8 g/day for 3 months (12) . However, the efficacy of curcumin in vitro was better than that in vivo which indicated a poor bioavailability (13, 14) . Piperine, an alkaloid present in black pepper (Piper nigrum) and long pepper (Piper longum), is known to enhance the bioavailability of a number of therapeutic agents including natural products (15) (16) (17) . It has been reported that the co-administration of piperine with curcumin enhanced the bioavailability of the latter in rats by 154% and in humans by 2000% probably by reducing the metabolic breakdown rate, increasing the residence time in the intestine, altering the membrane lipid dynamics and changing the conformation of enzymes in the intestine (18) (19) (20) .
Taurine, 2-aminoethanesulfonic acid, is an amino acid derivative that has the ability to scavenge oxygen free radicals with antitumor properties (21, 22) . Moreover, the addition of a certain amount of taurine to the drinking water of mice with transplanted tumors resulted in a decrease in the rate of tumor growth by 42.26%, with the extension of the mean lifespan (23) .
It has been shown that interleukin-10 (IL-10), a pleiotropic cytokine produced by macrophages, T-helper 2 (Th2) cells, and B-lymphocytes, inhibits various immune reactions (24) . This immunosuppressive effect may cripple macrophage activation and interferon-gamma production which are two potential mediators of antitumor response, and thus plays a major role in the development of neoplastic processes helping tumor cells to escape from host immune surveillance and potentiate them to metastasize (25) . In HCV-infected, cirrhotic, and HCC patients, serum IL-10 concentration was found to be elevated. Further, its levels were associated with disease progression indicating that IL-10 may reflect the degree of inflammation in the liver and may be related to the development of HCC (26) .
In HCC patients, the high serum level of IL-10 may be attributed to its secretion by tumor cells, in addition to the production at the site of inflammatory changes with activated infiltrating mononuclear cells in the liver (27) .
MicroRNAs (miRNAs) are short (19-22 nucleotides), endogenous and non-coding RNAs that play important regulatory functions in basic cellular processes by regulating gene expression at the posttranscriptional level. Additionally, they may act as tumor suppressors or oncogenes (28) .
Accumulating evidence suggests that miR-141 could function as a tumor suppressor in HCC by inhibiting the migration and invasion of tumor cells (29) (30) (31) . On the other hand, miR-21 was found to be highly over-expressed in HCC where it could modulate the expression of gene products involved in the phenotypic characteristics of cancer cells such as cell growth, migration, and invasion and thus may contribute to tumor growth and spread (32) (33) (34) .
Based on the existing evidence, this study was conducted to evaluate the effect of a natural agents' combination treatment, presented by curcumin, piperine, and taurine, on serum IL-10 level and the expression level of circulating miR-141 and miR-21 in patients with HCC. Patients previously treated with systemic chemotherapy could be enrolled after a washout period of at least 4 weeks.
Methods

Study population
Study design
Twenty patients, who fulfilled all the eligibility and exclusion criteria, took a 500 mg of taurine (Solgar, NJ, USA) once daily and eight capsules divided in a thricedaily regimen, each contained 500 mg of curcuminoids (70-80% curcumin, 15-25% demethoxycurcumin and 2.5-6.5% bisdemethoxycurcumin) and 5 mg of piperine as a bioavailability enhancer (Sabinsa Corp., NJ, USA), orally after food for three successive cycles; each was a 30-day cycle.
Patients received the best available supportive care during the study time and were followed-up for a total period of 24 months or until death, whichever occurred first.
Evaluation during the study
The primary endpoint in this study was the analysis of the combined treatment effect on serum IL-10 and miRNA expression levels. Therefore, their levels were measured prior to the administration of the treatment, and after each treatment cycle. Further, a complete history, physical examination, blood tests including a CBC with differential, renal and liver function tests, and alpha-L-fucosidase (AFU), were obtained in all patients at baseline, repeated every 30 days prior to the administration of the subsequent cycle, and after the last cycle.
IL-10 level
Serum level of IL-10 was measured by ELISA kit (Cat No. 950.060.096) according to the manufacturer's instruction (Diaclone Research, Besancon, France). The sensitivity of the assay was 5 pg/mL with an intra-, and interassay coefficients of variation (CV) of 3.5% and 7.5%, respectively. The test was performed on ChroMate ® microplate reader (Awareness Technology Inc., FL, USA).
miRNAs expression
Total RNA including miRNAs and other small noncoding RNAs >18 nucleotides were extracted from 100 μL of serum using miRNeasy serum/plasma kit (Qiagen)
according to the protocol provided by the manufacturer.
One μg of the total RNA was reverse transcribed to synthesize first cDNA strand using miScript II RT Kit 
Statistical analysis
Analyses were performed using SPSS version 20 (IBM Corp., NY, USA). The normality of data distribution was tested with the Shapiro-Wilk test; normally distributed data are expressed as mean ± SD, non-normally distributed data are expressed as median and interquartile range (25 th and 75 th percentile), and categorical variables are expressed as frequencies (percentages). Continuous variables were compared using ANOVA for repeated measures followed by Bonferroni correction for adjustment of multiple comparisons or Friedman's test followed by Dunn post hoc for multiple comparisons as appropriate. Overall survival (OS) with its corresponding 95% confidence interval (CI) was measured from the day of the first administration of the treatment till the date of death or the last follow up. The samples were divided into two groups (high vs. low) by a cutoff value which was determined as the median value for IL-10 and as the median value of the -ΔΔCt for miRNAs at the baseline level and the log-rank test was performed to assess the association between IL-10 and miRNAs levels with the time to survival along with Cox's proportional hazards models to estimate the hazard ratio (HR). Kaplan-Meier curves were used to visually examine the cumulative probability of remaining alive for IL-10 and miRNAs subgroups. All P values were 2-sided and a P value <0.05 was considered statistically significant.
Results
Patients' baseline characteristics
The patient baseline characteristics are described in Table 1 . The mean patients' age was 58.95±5.47 years; most of them (75%) had BCLC stage B disease and 60% were with ECOG performance status of 0. Moreover, 60% of patients had a tumor size >5 cm with median serum levels of 610 U/L for AFU and 37.92 pg/mL for IL-10 at the time of study entry. Table 2 shows that among the biochemical parameters, activities of ALT and AST in addition to total bilirubin and AFU levels in sera of HCC patients turned out to be decreased with the treatment relative to the baseline levels. Multiple comparisons showed that serum activities of ALT and AST and the level of AFU were significantly decreased after the first treatment cycle compared to those at the baseline (P=0.004, P=0.005, and P=0.040, respectively). Further, serum activities of ALT and AST and the levels of total bilirubin and AFU were significantly decreased after 60 days of treatment compared to the baseline levels (P=0.004, P<0.001, P=0.002, and P<0.001, respectively). On the other hand, total bilirubin level and the activities of ALT and AST were significantly decreased compared to those after one cycle of treatment (P=0.025, P=0.003, and P<0.001, respectively). After 3 cycles of treatment, serum activity of AST and the levels of total bilirubin and AFU showed a significant decrease compared to the baseline levels (P<0.001, P=0.001 and P<0.001, respectively), to those after one cycle of treatment (P=0.001, P<0.001, and P<0.001, respectively), and to those after two cycles of treatment (P=0.013, P=0.001, and P=0.019, respectively).
Variation of serum levels of some biochemical parameter before, during, and after the treatment
Serum activity of ALT was significantly decreased compared
only to the baseline level (P=0.001), and to that after one cycle of treatment (P=0.002).
Meanwhile, albumin level was significantly increased in sera of HCC patients only after three cycles of treatment in comparison with that at the baseline (P<0.001), and with that after 30 days of treatment (P=0.032).
Effect of treatment on serum IL-10 level
The combined treatment, composed of curcumin, piperine, and taurine, resulted in a significant decrease in the serum level of IL-10 after two cycles of treatment compared to the baseline level (P<0.001), and to that after 30 days of treatment (P=0.001). Additionally, serum IL-10 level after three treatment cycles showed a significant decrease in comparison with that at the baseline, as well as after one, and 2 cycles of treatment (P<0.001, P<0.001, and P=0.005, respectively) ( Table 2) .
Change of circulating miRNAs expression level in response to the treatment
With respect to miR-141, a non-significant up-regulation of its expression was observed after the second and the third treatment cycles either compared to the expression after the first cycle or compared to each other (P=0.549) ( Figure 1A) .
On the contrary, the expression of miR-21 was affected by the treatment showing a significant down-regulation between cycles (P<0.001). The expression was down-regulated by 4 folds after the second cycle and by 70 folds after the third cycle of treatment compared to the expression after the first cycle (P=0.006, and P<0.001, respectively). Further, the expression was down-regulated by 17 folds after the third cycle of treatment compared to that after the second one (P=0.006) ( Figure 1B) .
Association of IL-10 and miRNAs pre-treatment levels with the OS in HCC patients
All patients received the three cycles of treatment; 50% of patients were alive after one year with a median OS of 17.00 months (95% CI: 11.67-19.73).
Kaplan-Meier OS curves of HCC patients according
to the status of IL-10, miR-141, and miR-21 levels at the baseline were examined. Figure 2 indicates that the patients in the high IL-10 and the high miR-21 sub-groups showed Relative expression of miR-21
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Discussion
Curcumin was demonstrated by several preclinical studies as a promising anticancer drug (36) (37) (38) . This anticancer potential may attribute to its myriad biological properties which make it able to suppress the initiation, promotion, proliferation, and metastasis of a wide variety of malignant tumors (39) . However, poor bioavailability of curcumin was considered the major obstacle for its clinical application which can be overcome by the co-administration with piperine known to increase curcumin bioavailability in animals and humans (18) . In addition, it has been shown that taurine reduces the levels of pro-inflammatory cytokines and exerts an anti-cancer effect by inducing the apoptosis of cancer cells (40, 41) . Therefore, this study was designed to assess the effect of a combined therapy composed of curcumin, piperine, and taurine, on serum IL-10 level and the expression level of circulating miR-141 and miR-21 in patients with HCC.
The results of the current study revealed that high IL-10 level was a poor prognostic sign where the median OS of patients in the low IL-10 sub-group was 1.6 folds more than that of patients in the high IL-10 sub-group. This echoes previous studies indicating that the serum IL-10 level was an adverse prognostic factor for patients with inoperable HCC and in those after surgical resection (42) (43) (44) , confirms a predominantly immunosuppressive role of IL-10 for circulating dendritic cells in patients with HCC, and thus may indicate the aspects of tumor immune evasion (45) . The combined treatment was able to decrease IL-10 serum level significantly after 2 cycles of administration which can be attributed to the effect of the treatment on the signal transducer and activator of transcription3 (STAT3) which is a pro-inflammatory transcription factor known to be constitutively expressed and play a major role in the pathogenesis of several cancer types (46) . In cancer cells, STAT3 promotes the expression of factors that are both immunosuppressive and STAT3 activating, including vascular endothelial growth factor (VEGF) and IL-10. These tumor-derived factors, in turn, up-regulate STAT3 signaling in various immune-cell subsets in the tumor microenvironment, which produce more immunosuppressive factors, including IL-6, IL-10, transforming growth factor-β (TGF-β), and VEGF, thereby abrogating the function of various immune effector cells (47) (48) (49) . Several studies demonstrated that both curcumin and taurine were able to inhibit STAT3 activation (50) (51) (52) (53) (54) (55) . Thus, we can speculate that the decreased level of IL-10 upon administration of the combined treatment may be attributed to the negative effect of the treatment on STAT3 activation and consequently on the synthesis and secretion of IL-10.
In the same context, this work showed that the overexpression of the circulating miR-21 was associated with poor prognosis. The median OS of patients in the low miR-21 sub-group was almost the double of that in the high miR-21 sub-group. This is in agreement with the results of prior publications which reported that the OS rate of patients with high miR-21 expression was significantly worse than those of patients with low miR-21 expression in In HCC, miR-141 could function as a tumor suppressor by targeting the metastasis-related T lymphoma invasion and metastasis 1 (Tiam1) gene (29) . Moreover, a study by Xu et al. (67) suggested that over-expression of miR-141 suppressed HCC cell growth and invasion via targeting the transcription inhibitor zinc finger E-box-binding homeobox 2 (ZEB2). This study revealed that the down-regulation of the circulating miR-141 expression level may contribute to poor prognosis. The median OS of patients in the high miR-141 sub-group was as high as 1.7 folds of that in the low miR-141sub-group. This is in agreement with the results of Lu et al. (68) who showed that the down-regulation of miR-141 may contribute to the aggressive progression and poor prognosis of human gastric cancer. Further, it was found that miR-141 may act as an independent prognostic factor for pancreatic cancer patients (69) . Additionally, Wszolek et al. (70) suggested that miR-141 up-regulation could act as an independent indicator for favorable prognosis of bladder cancer. Unfortunately, the combined therapy resulted in a non-significant upregulation of the circulating miR-141 expression level.
In conclusion, the results of the present work support the notion that altered expression of serum IL-10, miR-21, and miR-141 may be prognostic biomarkers that may help to guide treatment in HCC. Further, in a population of patients with fairly advanced HCC, the administration of a combined treatment composed of curcumin, piperine, and taurine for three successive months was able to decrease the circulating level of IL-10 and miR-21, with no effect on miR-141 expression level, which may be reflected on the OS rate positively.
Study limitation
There were several limitations to our study. First, this was a single-center study so there are likely selection bias and limitation of the generalizability of the findings. Second, this was a preliminary study performed on a small sample size and more subjects would provide stronger statistical analyses. Finally, the evaluation in a randomized trial may be warranted to further delineate the potential clinical benefits and risks.
Despite these limitations, this study still had its own special advantages; to the best of our known, this is the first study that analyzed the effect of such a treatment on HCC patients which may open the way to new and promising therapeutic strategies. Additionally, if confirmed in further studies, this study showed that serum IL-10 and miR-21 may represent non-invasive biomarkers of the therapeutic response at least in terms of OS rate.
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